[go: up one dir, main page]

WO2007112097A3 - Novel signature self renewal gene expression programs - Google Patents

Novel signature self renewal gene expression programs Download PDF

Info

Publication number
WO2007112097A3
WO2007112097A3 PCT/US2007/007448 US2007007448W WO2007112097A3 WO 2007112097 A3 WO2007112097 A3 WO 2007112097A3 US 2007007448 W US2007007448 W US 2007007448W WO 2007112097 A3 WO2007112097 A3 WO 2007112097A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
leukemia
self renewal
expression programs
novel signature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/007448
Other languages
French (fr)
Other versions
WO2007112097A2 (en
Inventor
Andrei V Krivtsov
Scott A Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Priority to US12/294,195 priority Critical patent/US20090324618A1/en
Publication of WO2007112097A2 publication Critical patent/WO2007112097A2/en
Anticipated expiration legal-status Critical
Publication of WO2007112097A3 publication Critical patent/WO2007112097A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to compounds and methods which are useful in molecular investigations of target genes, as well as their encoded RNAs and protein, belonging to signature self renewal programs in leukemia and/or cancer stem cells. Data herein shows that leukemia stem cells can be generated from committed progenitors without widespread reprogramming of gene expression, and wherein a leukemia self-renewal associated signature is activated in the process.
PCT/US2007/007448 2006-03-24 2007-03-26 Novel signature self renewal gene expression programs Ceased WO2007112097A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/294,195 US20090324618A1 (en) 2006-03-24 2007-03-26 Novel signature self renewal gene expression programs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78553206P 2006-03-24 2006-03-24
US60/785,532 2006-03-24
US85202106P 2006-10-16 2006-10-16
US60/852,021 2006-10-16

Publications (2)

Publication Number Publication Date
WO2007112097A2 WO2007112097A2 (en) 2007-10-04
WO2007112097A3 true WO2007112097A3 (en) 2008-12-11

Family

ID=38541734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007448 Ceased WO2007112097A2 (en) 2006-03-24 2007-03-26 Novel signature self renewal gene expression programs

Country Status (2)

Country Link
US (1) US20090324618A1 (en)
WO (1) WO2007112097A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
US8354224B2 (en) 2006-03-20 2013-01-15 The Ohio State University MicroRNA fingerprints during human megakaryocytopoiesis
US8361722B2 (en) 2007-06-15 2013-01-29 The Ohio State University Research Foundation Method for diagnosing acute lymphomic leukemia (ALL) using miR-221
US8361710B2 (en) 2006-01-05 2013-01-29 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
US9125923B2 (en) 2008-06-11 2015-09-08 The Ohio State University Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
CN105988002A (en) * 2015-03-03 2016-10-05 南京鼓楼医院 Method for detecting endometrial receptivity through MST1 and phosphorylated MST1

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
CA2601623C (en) 2005-03-14 2018-10-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
WO2007016548A2 (en) 2005-08-01 2007-02-08 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
EP2796554A3 (en) 2005-09-12 2014-12-10 The Ohio State University Research Foundation Compositions for use in treating BCL2-associated cancers
EP2468895B1 (en) 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
CN103361424A (en) 2006-01-05 2013-10-23 俄亥俄州立大学研究基金会 MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
ES2447850T3 (en) 2006-07-13 2014-03-13 The Ohio State University Research Foundation Methods and compositions based on micro-RNA for the prognosis and treatment of diseases related to the colon
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
ES2537349T3 (en) 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods to determine a subtype of hepatocellular carcinoma
AU2008282318B2 (en) 2007-07-31 2014-02-27 The Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
EP2650383A1 (en) 2007-08-03 2013-10-16 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
CA2926831A1 (en) * 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
US20090093005A1 (en) * 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
US20090226956A1 (en) * 2008-02-07 2009-09-10 University Of Southern California Runx-mediated action of nuclear receptors and utilities thereof
PT3130923T (en) 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
CN106755415A (en) 2009-01-15 2017-05-31 小利兰·斯坦福大学托管委员会 Biomarker plate for diagnosing and predicting graft rejection
CN101781357B (en) * 2009-01-21 2012-01-11 中国科学院化学研究所 Polypeptide for detecting human cancer cells, and application thereof
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found SUBSTANCES AND METHODS THAT CAN BE USED TO ACT ON THE GROWTH, MIGRATION, AND INVASION OF TUMOR CELLS
EP2507630B1 (en) 2009-12-02 2017-01-25 The Board of Trustees of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
US9535075B2 (en) 2010-03-25 2017-01-03 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
ES2606146T3 (en) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Methods related to microRNA-21 and repair of disappearance in colorectal cancer
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
CN103459424B (en) 2011-01-19 2017-11-10 坎塔吉亚有限责任公司 ANTI-IL1RAP ANTIBODIES AND USES THEREOF FOR THERAPY OF HUMAN
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
CN104364390B (en) 2011-10-14 2016-08-24 俄亥俄州立大学 Methods and materials related to ovarian cancer
JP2015501843A (en) 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション Methods and compositions relating to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
AU2013209477B2 (en) 2012-01-20 2016-12-08 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
KR101970764B1 (en) 2017-05-19 2019-04-22 아주대학교산학협력단 COTL1 Protein Involved in Maintaining Homeostasis of Hematopoietic Stem Cells and Use Thereof
SG11202010260XA (en) 2018-04-25 2020-11-27 Childrens Medical Center Abcb5 ligands and substrates
CN116686783B (en) * 2023-06-26 2025-10-28 武汉大学 Construction methods, intervention targets and applications of animal models of paternally derived testicular dysplasia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARMSTRONG S.A. ET AL.: "MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia", NATURE GENETICS, vol. 30, January 2002 (2002-01-01), pages 41 - 47, XP002361721 *
AYTON P.M. ET AL.: "Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9", GENES & DEVELOPMENT, vol. 17, 2 September 2003 (2003-09-02), pages 2298 - 2307 *
CALVO K.R. ET AL.: "Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1", ONCOGENE, vol. 21, 2002, pages 4247 - 4256, XP003014727, DOI: doi:10.1038/sj.onc.1205516 *
HEINRICHS S. ET AL.: "CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome", BRITISH JOURNAL OF HAEMATOLOGY, vol. 130, 2005, pages 83 - 86 *
WANG G.G. ET AL.: "Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus", BLOOD, vol. 106, no. 1, 8 March 2005 (2005-03-08), pages 254 - 264 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361710B2 (en) 2006-01-05 2013-01-29 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21
US8377637B2 (en) 2006-01-05 2013-02-19 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P
US8354224B2 (en) 2006-03-20 2013-01-15 The Ohio State University MicroRNA fingerprints during human megakaryocytopoiesis
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
US8361722B2 (en) 2007-06-15 2013-01-29 The Ohio State University Research Foundation Method for diagnosing acute lymphomic leukemia (ALL) using miR-221
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
US9125923B2 (en) 2008-06-11 2015-09-08 The Ohio State University Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
CN105988002A (en) * 2015-03-03 2016-10-05 南京鼓楼医院 Method for detecting endometrial receptivity through MST1 and phosphorylated MST1

Also Published As

Publication number Publication date
US20090324618A1 (en) 2009-12-31
WO2007112097A2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2007112097A3 (en) Novel signature self renewal gene expression programs
IN2012DN00403A (en)
WO2006046148A3 (en) Rna constructs
WO2005059097A3 (en) Methods for high fidelity production of long nucleic acid molecules
WO2008080900A3 (en) Methionine synthases with reduced product inhibition
WO2009056566A3 (en) Plants having enhanced yield-related traits and a method for making the same
WO2009006297A3 (en) Methods for altering the genome of a monocot plant cell
WO2009003977A8 (en) Plants having enhanced yield-related traits and a method for making the same
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2009045370A3 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2008064837A8 (en) Novel genes for the fermentative production of hydroxytyrosol
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
WO2008067423A3 (en) Methods of improving the introduction of dna into bacterial cells
SG170819A1 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
MX2009009846A (en) Improving cold- and salt-tolerant performance of plants with transcription factor gene snac2 from rice.
WO2005111217A3 (en) Nicotiana nucleic acid molecules and uses thereof
WO2007135685A3 (en) Compositions for silencing the expression of gibberellin 2-oxidase and uses thereof
WO2009137145A3 (en) Transcriptional control in alicyclobacillus acidocaldarius and associated genes, proteins, and methods
WO2007062936A3 (en) Dna binding site of a transcriptional activator useful in gene expression
WO2008093847A1 (en) Dna encoding xylitol dehydrogenase
WO2008008967A3 (en) Methods for increasing expression of genes in a fungal cell
WO2010135836A8 (en) Novel beta-glucosidase enzymes
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754025

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12294195

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 07754025

Country of ref document: EP

Kind code of ref document: A2